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Radiation therapy (RT) remains a powerful single option with curative
intention in the local treatment of indolent primary cutaneous B‐cell
lymphoma (pcBCL). It is well known that (1) primary cutaneous mar-
ginal zone lymphoma (pcMZL) have a much higher relapse rate than
primary cutaneous follicle center lymphoma (pcFCL) after RT, (2)
pcFCL and pcMZL present at different skin sites, and (3) pcMZL much
more often present with multifocal lesions than pcFCL. We presented
an analysis of retrospective cohort investigating the role of initial RT in
patients with an indolent pcBCL.1 A radiation dose of 20 to 46 Gy was
prescribed. With 131 months (range, 25‐240) follow‐up, we concluded
that lesions at other sites than the trunk and the presence of multiple
lesions were associated with an increased relapse risk on the basis of a
difference in 5‐year relapse‐free survival (RFS) rate for patients with
trunk lesion versus those with other location (89.4% versus 66.9%)
and in case of single and multiple lesions (83.5% versus 57.1%,
P = .04). Several important issues still need to be discussed. First, the
multiple lesions definition could be a confounder. We classified
multifocal lesions as those lesions requiring different radiation fields.
Second, the substantial variation in radiation dose used (20 to
46 Gy) could potentially increase selection bias in this kind of analysis.
Indolent pcBCL is a high radioresponsive disease and dose over 30 Gy
is unusual, especially in radiosensitive organs such as the eye.2 With
regard to pcBCL, the high total dose up to 46 Gy was prescribed in
order to control the disease on a long‐term basis. We have reported
excellent clinical outcomes with 10‐year RFS and overall survival rates
of 71.1% and 87.1%, respectively. No in‐field recurrences were
observed.1 This high total dose could potentially improve severe late
toxicity, including the risk of RT‐induced second malignancies,
although dose distribution was just limited to skin zone. We recognize
that it could represent an overtreatment, based on current guidelines,2
but the tumor size at diagnosis could justify 30 to 46 Gy as an appro-
priate dose, when the intent for treatment was tumor eradication.
Surely, this was only one retrospective experience, but we believe it
could provide an appropriate tool for a better issue's awareness. The
use of low‐dose involved‐field RT for indolent pcBCL is generally
scheduled in palliative setting.2 Low doses of 4 Gy have been shownHematological Oncology. 2018;1–1. wileyonlinelibrary.com/journato be beneficial in 18 patients with low‐grade malignant cBCL.3
Results were interesting, reporting significant percentages of complete
response (75%) with a median time to local progression of approxi-
mately 10 months, without side effects.
In the end, our analysis is closer to demonstrating that RT is still
paramount in clinical management of patients with indolent pcBCL.
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